bta ann. is coming., page-16

I'll write the friggin release.

''BTA is pleased to advise that GSK has indicated it is increasing its Production capacity to 190 million packs.

The plans include a commitment by GSK to increase its annual production capacity of the influenza anti-viral Relenza to 190 million courses by the end of 2009. This increase represents a threefold increase to GSK�fs previous increased capacity of 60 million courses.

'Going forward BTA looks forward to an increased revenue stream due to this increased production.'' said a delighted Peter Cook.

GSK has confirmed to BTA that they have solid orders received that supports this increased production.""


Disclaimer (This is make beleive)